Hormonal
Tirzepatide treatment in adults with pre-existing type 2 diabetes significantly reduces the risk of major adverse cardiovascular events (MACE), including all-cause mortality and cerebral infarction, compared to semaglutide.
If you have type 2 diabetes, tirzepatide may offer greater cardiovascular protection than semaglutide, including a lower risk of heart attack, stroke, and death. This is based on real-world data showing a 46% lower risk of major adverse cardiovascular events with tirzepatide compared to semaglutide over a one-year follow-up period. Consult your doctor to see if this treatment is appropriate for you.
In individuals with pre-existing T2D (n = 8446), tirzepatide was associated with lower risk of the composite outcome (HR 0.54, 95% CI 0.38–0.76, p < 0.001), cerebral infarction (HR 0.45, 95% CI 0.24–0.84, p = 0.010) and all-cause mortality (HR 0.33, 95% CI 0.15–0.73, p = 0.004) compared to semaglutide.
Why this rating
Large retrospective cohort study (n=8,446) with propensity score matching, but observational design limits causal inference.
Source
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study
Matthew Anson et al. · EClinicalMedicine · 2024
DOI 10.1016/j.eclinm.2024.102777
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →